**Appendix 1**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Summary of HASPOC Waivers from 2012 through May 2018** | | | | | | | | | | |
|  |  | **Waiver Review Summary** | | | **Study Execution (Savings to the Registrant)** | | | | **Study Report Review by EPA Contractor (Savings to EPA)** | |
| Type of Study | OCSPP guideline | Waiver Requests | Waivers Granted | Required Studies | # animals/study | Total # animals saved | Cost/study | Total cost savings | Price to review study per EPA contract | Total Cost Savings |
| Subchronic Inhalation | 870.3465 | 296 | 233 | 63 | 80 | 18,640 | $587,500 | $136,887,500 | $3,426 | $798,258 |
| Neurotoxicity (ACN and SCN) | 870.6200 | 330 | 306 | 24 | 80 | 24,480 | $215,800 | $66,034,800 | $6,441 | $1,970,946 |
| 21/28-Day Dermal | 870.3200 | 62 | 55 | 7 | 80 | 4,400 | $116,400 | $6,402,000 | $3,426 | $188,430 |
| Developmental (rat and rabbit) | 870.3700 | 44 | 39 | 5 | 80 | 3,120 | $158,900 | $6,197,100 | $5,162 | $201,318 |
| DNT | 870.6300 | 21 | 19 | 2 | 1,100 | 20,900 | $787,000 | $14,953,000 | $10,326 | $196,194 |
| Subchronic dog | 870.3150 | 15 | 13 | 2 | 32 | 416 | $265,100 | $3,446,300 | $7,743 | $100,659 |
| Reproductive | 870.3800 | 38 | 34 | 4 | 2,600 | 88,400 | $440,600 | $14,980,400 | $12,354 | $420,036 |
| Immunotoxicity | 870.7800 | 229 | 223 | 6 | 16 | 3,568 | $72,600 | $16,189,800 | $8,075 | $1,800,725 |
| Chronic/Carcinogenicity | 870.4300 | 25 | 23 | 2 | 480 | 11,040 | $1,808,800 | $41,602,400 | $11,314 | $260,222 |
| Subchronic rat | 870.3100 | 15 | 12 | 3 | 80 | 960 | $177,000 | $2,124,000 | $7,743 | $92,916 |
| CTA | non-guideline | 20 | 15 | 5 | 1800 | 27,000 | $550,000 | $8,250,000 | $12,354 | $185,310 |
| **Totals** |  | **1095** | **972** | **123** |  | **202,924** |  | **$317,067,300** |  | **$6,215,014** |